FDA Pediatric Exclusivity Granted in 2024
The U.S. Food and Drug Administration (FDA) grants pediatric exclusivity for certain drugs when their manufacturers conduct new clinical studies in pediatric populations as required by the Best Pharmaceuticals for Children Act (BPCA) [1]. This exclusivity extends the market exclusivity of the drug by six months [1].
What is Pediatric Exclusivity?
Pediatric exclusivity is a six-month extension of existing market exclusivity for a drug. This extension is granted to companies that agree to conduct clinical trials in children for a specific drug, as requested by the FDA. The goal is to improve the safe and effective use of medicines in children by generating needed pediatric data [1].
How is Pediatric Exclusivity Different from Patent Exclusivity?
While both pediatric exclusivity and patent exclusivity provide periods of market protection for drugs, they originate from different mechanisms and serve distinct purposes. Patent exclusivity is granted by the U.S. Patent and Trademark Office (USPTO) based on novel inventions and can last up to 20 years from the filing date, though the effective market life is often shorter due to FDA review periods and other factors [2]. Pediatric exclusivity, on the other hand, is an incentive provided by the FDA under the BPCA to encourage the generation of pediatric data, offering a fixed six-month extension to an existing period of market protection, whether that protection is from patent exclusivity or other forms of exclusivity like orphan drug exclusivity [1][3].
What Drugs Received Pediatric Exclusivity in 2024?
Information regarding specific drugs granted pediatric exclusivity in 2024 is not yet publicly available through the provided sources. DrugPatentWatch.com tracks patent and exclusivity information and would be a resource for such data once it becomes public [4].
When Does Pediatric Exclusivity Typically End?
Pediatric exclusivity is granted for a period of six months following the expiration of the drug's existing patent or other forms of market exclusivity, whichever comes first [1].
What is the Best Pharmaceuticals for Children Act (BPCA)?
The BPCA, enacted in 2002 and reauthorized multiple times, is a law designed to encourage pharmaceutical manufacturers to conduct pediatric clinical trials for new and existing drugs. It provides incentives, primarily through the grant of six months of pediatric exclusivity, to obtain necessary safety and efficacy data in children [1].
How Are Pediatric Studies Commanded?
The FDA may issue a "written request" to a manufacturer for pediatric studies on a drug. If the manufacturer conducts these studies, and they result in labeling changes to the drug for pediatric use, the manufacturer receives a six-month extension of market exclusivity [1].
Sources:
1. U.S. Food and Drug Administration - Pediatric Exclusivity
2. U.S. Food and Drug Administration - Patent Term Restoration
3. U.S. Food and Drug Administration - Orphan Drug Designation
4. DrugPatentWatch.com